Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement

J Neurooncol. 1990 Dec;9(3):255-63. doi: 10.1007/BF02341156.

Abstract

A prospective study was performed in patients treated with cisplatin to evaluate the occurrence and degree of central, peripheral and autonomic neuropathy and to determine the most accurate method to study this neuropathy. Twelve patients were examined before, during and after treatment. Evaluation included neurologic examination, conventional nerve conduction studies of the median and peroneal nerves and short latency somatosensory evoked potentials (SSER) after median and tibial nerve stimulation. Valsalva maneuvers before and during treatment were performed in 11 patients. Symptoms of peripheral neuropathy paralleled clinical signs. Conventional nerve conduction studies did not seem to be more accurate than clinical examination in determining peripheral neuropathy. SSER appeared to be the most sensitive method for the detection of peripheral nerve impairment. A slowing of central conduction velocity occurred after cumulative doses of 200-400 mg/m2 as measured by SSER. In two patients also some involvement of the autonomic nerves was suggested.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Altretamine / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Autonomic Nervous System / drug effects
  • Autonomic Nervous System / physiopathology*
  • Central Nervous System / drug effects
  • Central Nervous System / physiopathology*
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects*
  • Cisplatin / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Evoked Potentials, Somatosensory / drug effects
  • Female
  • Humans
  • Middle Aged
  • Neural Conduction / drug effects
  • Ovarian Neoplasms / drug therapy*
  • Peripheral Nerves / drug effects
  • Peripheral Nerves / physiopathology*
  • Prospective Studies
  • Valsalva Maneuver

Substances

  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Altretamine

Supplementary concepts

  • CPDD protocol